Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Takeda
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and...
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA...
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...
Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP
Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour...
FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL
The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based...
Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...
Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio
Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...